New infusion drug tested for MASH cirrhosis
NCT ID NCT06675929
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 38 times
Summary
This study tested a new medicine called BI 770371 in 28 people with liver cirrhosis caused by MASH. Participants received either the drug or a placebo as an infusion every 3 weeks for 12 weeks. The main goal was to see if the drug is safe and tolerable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
American Research Corporation at the Texas Liver Institute
San Antonio, Texas, 78215, United States
-
Blessed Health Care
Miami, Florida, 33174-3245, United States
-
Catalina Research Institute, LLC-Montclair-49051
Montclair, California, 91763, United States
-
Evolution Clinical Trials
Miami, Florida, 33122, United States
-
Houston Research Institute
Houston, Texas, 77079, United States
-
Inland Empire Clinical Trials, LLC
Rialto, California, 92377, United States
-
Knowledge Research Center
Orange, California, 92868, United States
-
Peak Gastroenterology Associates-Colorado Springs-67762
Colorado Springs, Colorado, 80907, United States
-
Pinnacle Clinical Research, LLC
San Antonio, Texas, 78229, United States
-
Progressive Medical Research
Port Orange, Florida, 32127, United States
-
Southern California Research Center
Coronado, California, 92118, United States
-
The Institute for Liver Health II dba Arizona Clinical Trials
Chandler, Arizona, 85225, United States
-
The Liver Institute at Methodist Dallas
Dallas, Texas, 75203, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 770371 (given as an infusion into a vein)
What this could lead to
If it works, this could point toward a treatment that slows or stops liver damage in people with MASH-related cirrhosis.
What could go wrong
This is a very early, small Phase 2a trial focused on safety, not effectiveness. The drug may not improve liver health and could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.